Australia's Imugene up on positive early signs in cancer drug study

Imugene

06/11/2023 02:49

** Shares of Imugene  IMU.AX  rise 16.7% to A$0.056 after co
sees positive early signs from a potential cancer drug study
    ** Stock among top 10 gainers in the ASX All Ordinaries
index  .AORD 
    ** Co says it sees positive early signs from its early-stage
study testing the efficacy of cancer-killing virus VAXINIA
    ** Says early results from six patients with
gastrointestinal cancers who received VAXINIA alone showed
positive effects, with a disease control rate of 75%
    ** VAXINIA may be a potent anti-cancer drug, says MD & CEO
Leslie Chong
    ** Stock hits highest level since Sept. 19; on track for
third straight day of gains
    ** More than 56.2 mln shares change hands, vs the 30-day
average volume of 25.3 mln shares

 (Reporting by Aaditya Govind Rao in Bengaluru)
 ((Aaditya.govindrao@thomsonreuters.com;))